---
title: "Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge"
description: "Bruker Corporation's (NASDAQ:BRKR) share price has dropped 31% over the past month, resulting in a 51% loss for shareholders over the last year. Despite this decline, its price-to-sales (P/S) ratio of"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/252385324.md"
published_at: "2025-08-10T15:35:38.000Z"
---

# Why Investors Shouldn't Be Surprised By Bruker Corporation's (NASDAQ:BRKR) 31% Share Price Plunge

> Bruker Corporation's (NASDAQ:BRKR) share price has dropped 31% over the past month, resulting in a 51% loss for shareholders over the last year. Despite this decline, its price-to-sales (P/S) ratio of 1.3x suggests it may still be a buying opportunity compared to industry peers. However, analysts predict Bruker's revenue growth will lag behind the industry, with a forecast of only 3.2% growth per year versus the industry's 6.8%. This expectation of limited future growth is reflected in the low P/S ratio, indicating potential barriers for the share price.

Explore Bruker's Fair Values from the Community and select yours

The **Bruker Corporation** (NASDAQ:BRKR) share price has fared very poorly over the last month, falling by a substantial 31%. The recent drop completes a disastrous twelve months for shareholders, who are sitting on a 51% loss during that time.

Although its price has dipped substantially, Bruker may still look like a strong buying opportunity at present with its price-to-sales (or "P/S") ratio of 1.3x, considering almost half of all companies in the Life Sciences industry in the United States have P/S ratios greater than 3.5x and even P/S higher than 6x aren't out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it's justified.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

View our latest analysis for Bruker

### How Has Bruker Performed Recently?

Bruker certainly has been doing a good job lately as it's been growing revenue more than most other companies. It might be that many expect the strong revenue performance to degrade substantially, which has repressed the share price, and thus the P/S ratio. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

Keen to find out how analysts think Bruker's future stacks up against the industry? In that case, our **free** report is a great place to start.

## What Are Revenue Growth Metrics Telling Us About The Low P/S?

In order to justify its P/S ratio, Bruker would need to produce anemic growth that's substantially trailing the industry.

Taking a look back first, we see that the company managed to grow revenues by a handy 10% last year. Pleasingly, revenue has also lifted 39% in aggregate from three years ago, partly thanks to the last 12 months of growth. Accordingly, shareholders would have definitely welcomed those medium-term rates of revenue growth.

Shifting to the future, estimates from the eleven analysts covering the company suggest revenue should grow by 3.2% per year over the next three years. Meanwhile, the rest of the industry is forecast to expand by 6.8% per year, which is noticeably more attractive.

With this information, we can see why Bruker is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

## What Does Bruker's P/S Mean For Investors?

Shares in Bruker have plummeted and its P/S has followed suit. While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.

We've established that Bruker maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. Unless these conditions improve, they will continue to form a barrier for the share price around these levels.

Plus, you should also learn about these **3 warning signs we've spotted with Bruker** (including 1 which can't be ignored).

If you're **unsure about the strength of Bruker's business**, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

### Related Stocks

- [BRKR.US - Bruker](https://longbridge.com/en/quote/BRKR.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 这些分析师在布鲁克公布第四季度业绩后下调了他们的预测 | 布鲁克公司（NASDAQ:BRKR）公布了混合的第四季度业绩，收益为每股 59 美分，低于预期的 65 美分，但销售额为 9.772 亿美元，超过了预期的 9.608 亿美元。该公司预计 2026 财年的调整后每股收益为 2.10 至 2. | [Link](https://longbridge.com/en/news/275927262.md) |
| 布鲁克公司第四季度收入因生物制药市场的复苏而超出预期 | 布鲁克公司报告 2025 年第四季度收入为 9.772 亿美元，超出分析师预期的 9.6083 亿美元，尽管同比增长持平。然而，调整后的每股收益为 0.59 美元，低于 0.65 美元的预期。公司预计 2026 财年的收入增长为 4% 至  | [Link](https://longbridge.com/en/news/275752855.md) |
| 阿彻丹尼尔斯米德兰｜10-K：2025 财年营收 803 亿美元不及预期 |  | [Link](https://longbridge.com/en/news/276167327.md) |
| OpenClaw 之父爆猛料：Meta 和 OpenAI 跪着抢人，小扎亲自求收购 | 在一场重磅播客访谈中，OpenClaw 之父 Peter Steinberger 透露，Meta 的扎克伯格和 OpenAI 的 Sam Altman 都在积极拉拢他，甚至扎克伯格亲自表示对 OpenClaw 的赞赏。两大科技巨头同时争抢人 | [Link](https://longbridge.com/en/news/275962731.md) |
| 马斯克的 “新大饼”：月球基地 | 马斯克以 “月球基地 Alpha” 新叙事替代火星计划，拟在月球制造并发射 AI 卫星以突破算力瓶颈。此举旨在整合 SpaceX 发射能力与 xAI 算力需求，打造差异化估值，虽技术壁垒极高，但为合并实体注入增长想象。 | [Link](https://longbridge.com/en/news/275864051.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
